Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1

Status

Completed 10Unknown 4Recruiting 4Active not recruiting 4Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Non-Small Cell Lung Cancer With HER2- Mutations 1Lung Neoplasms 1First-line Advanced NSCLC Patients 1

Interventions

Carboplatin 181pembrolizumab 156Pemetrexed 129Cisplatin 97Drug Therapy 67Paclitaxel 59osimertinib 56Magnetic Resonance Spectroscopy 50durvalumab 49Specimen Handling 49Radiotherapy 49Nivolumab 49atezolizumab 43Docetaxel 43Etoposide 40Bevacizumab 39Blood Specimen Collection 33tislelizumab 31Radiosurgery 31Gemcitabine 29130-nm albumin-bound paclitaxel 27Immunotherapy 25Immune Checkpoint Inhibitors 25cemiplimab 23Injections 23aflutinib 20Cetuximab 18Biopsy 18Standard of Care 17Platinum Compounds 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × CP protocol × Thoracic × Clear all
NCT05061550 2026-05-22

NeoCOAST-2

AstraZeneca

Phase 2 Recruiting
630 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07365319 2026-05-20

TeLuRide-008

Eikon Therapeutics

Phase 2/3 Recruiting
750 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06430437 2026-01-21

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
300 enrolled
Thoracic

Non-Small Cell Lung Cancer With HER2- Mutations

NCT07171606 2025-12-18

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 2 Recruiting
240 enrolled
Thoracic

First-line Advanced NSCLC Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡